Rosacea — a chronic inflammatory skin condition characterized by persistent facial redness, telangiectasia, papulopustules, and in advanced cases, phymatous skin changes or ocular involvement — affects an estimated 5% of the adult population worldwide, with prevalence increasing with age. Despite its prevalence, rosacea remains significantly underdiagnosed and undertreated, partly due to confusion between subtypes with distinct pathophysiology and optimally different treatments. The 2023 updated National Rosacea Society expert consensus panel guidelines incorporate new understanding of Demodex mites as drivers of inflammatory rosacea, novel topical agents, and refined subtype-specific treatment algorithms.
Rosacea Subtypes: Distinct Pathophysiology
Erythematotelangiectatic (ETR) — Subtype 1: Persistent central facial redness with visible telangiectasia, sensitive/reactive skin, frequent flushing. Pathophysiology: neurovascular dysregulation, abnormal toll-like receptor 2 (TLR2) expression amplifying inflammatory responses to normal facial stimuli. Treatment: trigger avoidance, vascular laser/IPL for telangiectasia, topical brimonidine (Mirvaso) for acute erythema reduction. Papulopustular — Subtype 2: Inflammatory papules and pustules resembling acne but without comedones. Pathophysiology: Demodex mite overpopulation (>5 mites/cm² vs. normal <1), innate immune activation, antimicrobial peptide upregulation. Treatment: topical azelaic acid, ivermectin 1% cream (Soolantra), topical metronidazole; oral doxycycline 40mg modified-release (subantimicrobial dose) for moderate-to-severe. Phymatous — Subtype 3: Skin thickening and surface irregularity, most commonly rhinophyma. Treatment: surgical (ablative laser, dermabrasion, electrosurgery) for established phyma; anti-inflammatory treatments to prevent progression. Ocular — Subtype 4: Lid margin disease, conjunctival injection, corneal involvement in severe cases. Treatment: lid hygiene, warm compresses, cyclosporine eyedrops, doxycycline systemically for ocular involvement.
Topical Ivermectin: The Demodex-Targeted Advance
The 2014 FDA approval of ivermectin 1% cream (Soolantra) for papulopustular rosacea was a landmark for rosacea management, directly targeting Demodex mite overpopulation for the first time in an approved formulation. Phase 3 trials: ivermectin 1% once daily achieved significantly superior reduction in inflammatory lesion counts compared to metronidazole 0.75% twice daily (74% vs. 58% reduction at 16 weeks), with significantly lower relapse rate at 36 weeks. Meta-analyses confirm ivermectin superiority to metronidazole for papulopustular rosacea. The mechanism likely involves both direct acaricidal activity against Demodex and anti-inflammatory effects of ivermectin that are independent of its antiparasitic activity. Skincare clinics and dermatology practices should maintain comprehensive stocks of post-procedure skin care products through our skin care catalog.
